Medicines Evaluation Unit Limited
UK company · Hampshire · incorporated 1999
Is this your company? Claim this profile ›
How it compares
Medicines Evaluation Unit Limited against its county.
Turnover for the 20 largest companies we track in Hampshire, from their filed accounts.
County at a glance
- Top 20 combined turnover
- £669m
- Average per company
- £33.4m
- This company vs average
- 0.5×
Filing timeline
On time, on the record.
Key dates from the Companies House register.
Incorporated
28 May 1999
Accounts made up to
31 Mar 2025
Latest filing: Confirmation statement
10 Jun 2026
Next accounts due
30 Sep 2026
Online presence
Digital score: Emerging
Our 0–1 score for how established and consistent a company's online presence is, compared with the Hampshire average.
- This company 0.21
- County average 0.27
Analysis
What the filings tell us.
Introduction
Medicines Evaluation Unit Limited holds a prominent position within the local commercial landscape, currently securing the tenth position among twenty monitored entities in Hampshire. As a significant player, their operational history remains accessible via the Companies House registration 03779957. While their current status remains pending verification, the firm is classified as having Emerging digital strength. This designation suggests an entity that is currently in a transitional phase regarding its online presence and data reporting sophistication, requiring stakeholders to rely on Archive Partners Hampshire intelligence to bridge the gap between static filings and real-time corporate transparency.
Regional Footprint
The economic contribution of Medicines Evaluation Unit Limited is notable, with their annual turnover of 18.2 million pounds representing approximately 2.7 percent of the collective output monitored across our Hampshire cohort. This financial volume positions the firm as a vital contributor to the local supply chain, likely supporting a substantive employment tier commensurate with mid-sized specialized clinical services. For procurement leads, this revenue share highlights the firm as a material partner whose operational continuity is essential for the stability of the wider Hampshire business financial performance metrics observed by our analytical team.
Digital Benchmark
The classification of the firm as Emerging places them broadly in line with the regional average for digital maturity. For credit analysts and ESG auditors, this alignment suggests that the company maintains a standard approach to digital communication, neither lagging significantly nor leading the market in technical transparency. Achieving parity with the county average is a baseline expectation for mature entities, yet it invites closer scrutiny regarding Hampshire company digital compliance. Investors should view this as a neutral signal, indicating that while internal systems are functional, there is room for improved disclosure maturity.
Financial Health Signals
Analyzing the firm requires looking beyond a standard Medicines Evaluation Unit Limited Companies House lookup. The company maintains a consistent fiscal narrative, yet its visibility is defined by a modest footprint of ten indexed search signals. This limited trail suggests a relatively closed operational structure, which can occasionally signal higher opacity for external observers. By integrating SIC-peer benchmarking against other entities in Hampshire, we assess that their governance quality aligns with typical expectations for this turnover bracket. Increased digital activity would serve as a positive indicator, effectively reducing the risk profile for prospective financial partners.
Watchlist Signals
Subscribers monitoring this entity should prioritize the observation of specific governance triggers that impact risk assessments. Key areas for active oversight include the timing of iXBRL filings, which serve as a primary indicator of administrative discipline, and any unexpected director change events that might signal a shift in strategic direction. Furthermore, tracking the trajectory of their search footprint is essential for gauging shifts in market engagement. For a procurement lead, evaluating how the firm moves relative to its SIC peers provides actionable intelligence, allowing for early detection of potential volatility within their primary sector of operations.
Market Outlook
Looking toward the next twenty-four months, the outlook for a firm of this scale within the Hampshire ecosystem remains cautiously optimistic. While the broader economic climate presents general headwinds for service-based industries, the company is well-positioned to leverage its current turnover to maintain market share. Archive Partners Hampshire suggests that the most critical metric for the upcoming filing cycle is the stability of revenue growth relative to industry-wide fluctuations. We recommend that stakeholders weight qualitative governance indicators heavily, as the company’s ability to navigate regulatory transitions will determine its long-term competitive resilience in this region.
All data is based on the latest digital audit and is subject to change without notice. Rankings and scores are updated periodically as new regulatory and web intelligence signals are processed. To report a data discrepancy, please contact our support team.
Claim this profile to manage Medicines Evaluation Unit Limited’s compliance record, respond to signals, and add verified contact details.
Written with AI assistance from filed data and our scores. Check key facts against the company record.
For developers
This whole profile, in one API call.
Pull the same record, scores and analysis into your CRM, spreadsheet or app. Add only the fields you need.
GET https://api.archive.partners/v1/marketintel/benchmark/companies/03779957?fields[]=introduction&fields[]=financial_health_signals&fields[]=market_outlook{
"company_id": "03779957",
"company_name": "Medicines Evaluation Unit Limited",
"county": "Hampshire",
"county_rank": 10,
"turnover_millions": 18.19,
"postcode": "RG1 3JH",
"fields": {
"introduction": "Medicines Evaluation Unit Limited holds a prominent position within the local commercial landscape, current...",
"financial_health_signals": "Analyzing the firm requires looking beyond a standard Medicines Evaluation Unit Limited Companies House loo...",
"market_outlook": "Looking toward the next twenty-four months, the outlook for a firm of this scale within the Hampshire ecosy..."
}
}All six analysis sections are available as fields. Add only the ones you need.
Hiring now
Live jobs at Medicines Evaluation Unit Limited
- Loading live vacancies…
Related companies
Stay ahead
Watch Medicines Evaluation Unit Limited, and companies like it.
Get an alert when they file accounts, cross a threshold or change directors.